BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 28099946)

  • 1. Long non-coding RNA ZFAS1 interacts with miR-150-5p to regulate Sp1 expression and ovarian cancer cell malignancy.
    Xia B; Hou Y; Chen H; Yang S; Liu T; Lin M; Lou G
    Oncotarget; 2017 Mar; 8(12):19534-19546. PubMed ID: 28099946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SP1-induced lncRNA-ZFAS1 contributes to colorectal cancer progression via the miR-150-5p/VEGFA axis.
    Chen X; Zeng K; Xu M; Hu X; Liu X; Xu T; He B; Pan Y; Sun H; Wang S
    Cell Death Dis; 2018 Sep; 9(10):982. PubMed ID: 30250022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting miR-21-3p inhibits proliferation and invasion of ovarian cancer cells.
    Báez-Vega PM; Echevarría Vargas IM; Valiyeva F; Encarnación-Rosado J; Roman A; Flores J; Marcos-Martínez MJ; Vivas-Mejía PE
    Oncotarget; 2016 Jun; 7(24):36321-36337. PubMed ID: 27166999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long noncoding RNA ZFAS1 promotes tumorigenesis through regulation of miR-150-5p/RAB9A in melanoma.
    Liang L; Zhang Z; Qin X; Gao Y; Zhao P; Liu J; Zeng W
    Melanoma Res; 2019 Dec; 29(6):569-581. PubMed ID: 30889053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long Non-coding RNA Zinc Finger Antisense 1 (ZFAS1) Regulates Proliferation, Migration, Invasion, and Apoptosis by Targeting MiR-7-5p in Colorectal Cancer.
    Mo D; Liu W; Li Y; Cui W
    Med Sci Monit; 2019 Jul; 25():5150-5158. PubMed ID: 31295229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of miR-224-5p is associated with the original cisplatin resistance of ovarian papillary serous carcinoma.
    Zhao H; Bi T; Qu Z; Jiang J; Cui S; Wang Y
    Oncol Rep; 2014 Sep; 32(3):1003-12. PubMed ID: 25017423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells.
    Zhu X; Shen H; Yin X; Long L; Chen X; Feng F; Liu Y; Zhao P; Xu Y; Li M; Xu W; Li Y
    Oncotarget; 2017 Jun; 8(24):39154-39166. PubMed ID: 28388577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-219-5p inhibits the proliferation, migration, and invasion of epithelial ovarian cancer cells by targeting the Twist/Wnt/β-catenin signaling pathway.
    Wei C; Zhang X; He S; Liu B; Han H; Sun X
    Gene; 2017 Dec; 637():25-32. PubMed ID: 28890378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Thyroid Receptor Interacting Protein 6 by MicroRNA-589-5p Inhibits Cell Proliferation, Migration, and Invasion in Endometrial Carcinoma.
    Wang Y; Dong L; Liu Y
    Cancer Biother Radiopharm; 2019 Oct; 34(8):529-536. PubMed ID: 31424277
    [No Abstract]   [Full Text] [Related]  

  • 10. Dysregulation of lnc-SNHG1 and miR-216b-5p correlate with chemoresistance and indicate poor prognosis of serous epithelial ovarian cancer.
    Pei ML; Zhao ZX; Shuang T
    J Ovarian Res; 2020 Dec; 13(1):144. PubMed ID: 33302997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The lncRNA CRNDE promotes colorectal cancer cell proliferation and chemoresistance via miR-181a-5p-mediated regulation of Wnt/β-catenin signaling.
    Han P; Li JW; Zhang BM; Lv JC; Li YM; Gu XY; Yu ZW; Jia YH; Bai XF; Li L; Liu YL; Cui BB
    Mol Cancer; 2017 Jan; 16(1):9. PubMed ID: 28086904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. S100A7 Regulates Ovarian Cancer Cell Metastasis and Chemoresistance Through MAPK Signaling and Is Targeted by miR-330-5p.
    Lin M; Xia B; Qin L; Chen H; Lou G
    DNA Cell Biol; 2018 May; 37(5):491-500. PubMed ID: 29485916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RhoC is a major target of microRNA-93-5P in epithelial ovarian carcinoma tumorigenesis and progression.
    Chen X; Chen S; Xiu YL; Sun KX; Zong ZH; Zhao Y
    Mol Cancer; 2015 Feb; 14(1):31. PubMed ID: 25649143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOXD1 is targeted by miR-30a-5p and miR-200a-5p and suppresses the proliferation of human ovarian carcinoma cells by promoting p21 expression in a p53-independent manner.
    Wang Y; Qiu C; Lu N; Liu Z; Jin C; Sun C; Bu H; Yu H; Dongol S; Kong B
    Int J Oncol; 2018 Jun; 52(6):2130-2142. PubMed ID: 29620165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transketolase is upregulated in metastatic peritoneal implants and promotes ovarian cancer cell proliferation.
    Ricciardelli C; Lokman NA; Cheruvu S; Tan IA; Ween MP; Pyragius CE; Ruszkiewicz A; Hoffmann P; Oehler MK
    Clin Exp Metastasis; 2015 Jun; 32(5):441-55. PubMed ID: 25895698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-141 enhances anoikis resistance in metastatic progression of ovarian cancer through targeting KLF12/Sp1/survivin axis.
    Mak CS; Yung MM; Hui LM; Leung LL; Liang R; Chen K; Liu SS; Qin Y; Leung TH; Lee KF; Chan KK; Ngan HY; Chan DW
    Mol Cancer; 2017 Jan; 16(1):11. PubMed ID: 28095864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long noncoding RNA H19 contributes to gallbladder cancer cell proliferation by modulated miR-194-5p targeting AKT2.
    Wang SH; Wu XC; Zhang MD; Weng MZ; Zhou D; Quan ZW
    Tumour Biol; 2016 Jul; 37(7):9721-30. PubMed ID: 26803515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The mannose receptor LY75 (DEC205/CD205) modulates cellular phenotype and metastatic potential of ovarian cancer cells.
    Faddaoui A; Bachvarova M; Plante M; Gregoire J; Renaud MC; Sebastianelli A; Gobeil S; Morin C; Macdonald E; Vanderhyden B; Bachvarov D
    Oncotarget; 2016 Mar; 7(12):14125-42. PubMed ID: 26871602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression.
    Chen WT; Yang YJ; Zhang ZD; An Q; Li N; Liu W; Yang B
    J Ovarian Res; 2017 Jan; 10(1):1. PubMed ID: 28086946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Up-regulation of miR-383-5p suppresses proliferation and enhances chemosensitivity in ovarian cancer cells by targeting TRIM27.
    Jiang J; Xie C; Liu Y; Shi Q; Chen Y
    Biomed Pharmacother; 2019 Jan; 109():595-601. PubMed ID: 30399596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.